💊 Get Daily Updates on Generic Entry, Litigation, Biosimilars, and More…
Profile for Alnylam Pharmaceuticals, Inc. (ALNY)
« Back to company indexALNY Chatter Timeline
Stock Ticker for ALNY
Most Active Tweeters for ALNY
| User | Tweets |
|---|---|
| @StckPro | 10 |
| @newsfilterio | 5 |
| @Tickeron | 5 |
| @bthefirsttoknow | 4 |
| @StockNewsBot2 | 3 |
Recent Tweets for ALNY
 |
@BinfoTrends RT @mRNAdisrupts: #Regulus Therapeutics Announces Successful Completion of Pre-IND Meeting with #FDA for RGLS8429 - PR Newswire $rgls $alny… January 25th 2022, 9:01pm |
 |
@SweepCastApp SweepCast alerted: $ALNY with Unusual Options Activity Alerted on $180 PUT Expiring: 03-18-2022 worth 52K? |? Check… https://t.co/AFVwh81ZpT January 25th 2022, 11:01am |
 |
@john_bresnahan RT @ByMadeleineA: $ALNY touts long-term data with vutrisiran, but investors really want to know what's going to happen with Apollo-B study… January 24th 2022, 4:01pm |
 |
@ByMadeleineA $ALNY touts long-term data with vutrisiran, but investors really want to know what's going to happen with Apollo-B… https://t.co/1wNQVpjONE January 24th 2022, 4:01pm |
 |
@KateMil39656637 $ALNY~Find active market alerts here in this best trading community.https://t.co/Yh9vzkg7nb January 24th 2022, 3:01pm |
 |
@newsfilterio Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2021 Financial Results $ALNY https://t.co/mWHG38bc2I January 24th 2022, 1:01pm |
 |
@otcdynamics $ALNY Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2021 Financial Results https://t.co/tiSASNjezg January 24th 2022, 1:01pm |
 |
@StckPro $ALNY NEW ARTICLE : Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2021 Financial Resul… https://t.co/bpG1DLe1dD January 24th 2022, 1:01pm |
|
@StckPro $MRK $ALNY NEW ARTICLE : Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Merck & Company… https://t.co/BfAMgcQBao January 24th 2022, 1:01pm |
 |
@StockNewsBot2 $ALNY Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2021 Financial Results https://t.co/Cg1FW8gkMc January 24th 2022, 1:01pm |
 |
@stock_titan $ALNY Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2021 Financial Results https://t.co/c6DvUfX2IN January 24th 2022, 1:01pm |
 |
@bthefirsttoknow First out// $ALNY: Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2021 Financial Results https://t.co/E8xo1P0akm January 24th 2022, 1:01pm |
|
@StckPro $ALNY NEW ARTICLE : BMO Capital Keeps Their Hold Rating on Alnylam Pharma (ALNY) https://t.co/ePUDlSIuyw Get all th… https://t.co/G6YJzJAHUL January 24th 2022, 12:01pm |
|
@StckPro $ALNY NEW ARTICLE : H.C. Wainwright Thinks Alnylam Pharma’s Stock is Going to Recover https://t.co/hqGPTRRNG6 Get a… https://t.co/1PET7AidV2 January 24th 2022, 11:01am |
|
@StckPro $ALNY $RVPH NEW ARTICLE : Analysts Are Bullish on Top Healthcare Stocks: Alnylam Pharma (ALNY), Reviva Pharmaceutic… https://t.co/ylANvAiqlU January 24th 2022, 11:01am |
 |
@AITRADEIDEAS Alnylam Shares Relatively Quiet As Hearing Dealreporter Recirculates Speculation Of Takeover $ALNY https://t.co/S7tGvRAhPK @benzinga January 24th 2022, 3:01am |
 |
@Sarah_Katilyn $ALNY let's switch it up and toss a large capper in the mix shall we https://t.co/smgAc0bBPE January 23rd 2022, 10:01pm |
 |
@Tickeron $ALNY's 10-day Moving Average moved below its 50-day Moving Average on January 3, 2022. View odds for this and othe… https://t.co/32pzD6DB4x January 23rd 2022, 1:01pm |
 |
@PenkeTrading I found you a Death Cross on the daily chart of Alnylam Pharmaceuticals Inc. $ALNY $ALNY.NASDAQ #deathcross… https://t.co/wJNM2px5VU January 23rd 2022, 3:01am |
|
@SweepCastApp SweepCast alerted: $ALNY with Unusual Options Activity Alerted on $150 PUT Expiring: 01-21-2022 worth 39K? |? Learn… https://t.co/Dt5aatkVi0 January 23rd 2022, 12:01am |
|
@Tickeron $ALNY's 10-day Moving Average crossed below its 50-day Moving Average on January 3, 2022. View odds for this and ot… https://t.co/kIcIF000Bp January 22nd 2022, 6:01pm |
|
@newsfilterio Alnylam: Biotech To Watch With Potential FDA Approval Of Vutrisiran For Rare Disease $ALNY https://t.co/zuF1RWxdPg January 22nd 2022, 4:01pm |
|
@StckPro $ALNY NEW ARTICLE : Alnylam: Biotech To Watch With Potential FDA Approval Of Vutrisiran For Rare Disease… https://t.co/jBxrfEWLse January 22nd 2022, 4:01pm |
 |
@SeekingAlpha $ALNY - Alnylam: Biotech To Watch With Potential FDA Approval Of Vutrisiran For Rare Disease.… https://t.co/nfQOJlsknf January 22nd 2022, 4:01pm |
 |
@SharonC22112717 $ALNY *Hey guys, I've made $55K with them in a week, by their alerts ,,_, https://t.co/eSAhmWl4Bw January 22nd 2022, 4:01am |
 |
@NEWZHQ RT @OryoJohn: $ALNY: Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with… January 21st 2022, 10:01pm |
 |
@MarcJacksonLA $ALNY Alnylam touts data replication for next-generation Onpattro in ATTR trial but analysts pour some cold water https://t.co/aT4f0y6rOU January 21st 2022, 10:01pm |
 |
@MaisaCorp $ALNY saying vutrisiran, an investigational RNAi therapeutic being developed to treat transthyretin-mediated amyloi… https://t.co/2yTnCGBFbg January 21st 2022, 10:01pm |
|
@bthefirsttoknow First out// $ALNY: A Bearish Sign Appears On Alnylam Pharmaceuticals's Chart https://t.co/xzBv7nAxw5 January 21st 2022, 2:01pm |
 |
@govermentchild $alny added to my postition January 21st 2022, 2:01pm |
|
@newsfilterio Alnylam' Reveals Detailed 18-Month Data From Vutrisiran Trial In Inherited Disease $ALNY https://t.co/p3Aqt3UihL January 21st 2022, 2:01pm |
|
@MarcJacksonLA $ALNY Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patie… https://t.co/DddEtkWakc January 21st 2022, 2:01pm |
 |
@Briefingcom $ALNY: Alnylam Pharma Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran.… https://t.co/1EmtA1kv1Y January 21st 2022, 2:01pm |
|
@MarcJacksonLA $ALNY Yvonne Greenstreet Aims to Take Alnylam to the Top 5 by ’25 | BioSpace https://t.co/fB8QqMnZ4L #jobs January 21st 2022, 2:01pm |
 |
@GetOnTrade $ALNY Alnylam Highlights 18Month Results From HELIOSA Phase 3 Study Of Vutrisiran All Secondary Endpoints Were Met… https://t.co/XrAH29hi8z January 21st 2022, 1:01pm |
 |
@Gambiste1 RT @WebChronicleTo1: $ALNY Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients… January 21st 2022, 12:01pm |
 |
@OryoJohn $ALNY: Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Pati… https://t.co/FbBgZdlegs January 21st 2022, 12:01pm |
 |
@newsinthemarket Alnylam announces HELIOS-A study meets all secondary endpoints $ALNY January 21st 2022, 12:01pm |
 |
@FlashAlert_me $ALNY [15s. delayed]: Issued Press Release on January 21, 07:30:00: Alnylam Presents Positive 18-Month Results from… https://t.co/41WSpEBoao January 21st 2022, 12:01pm |
|
@StockNewsBot2 $ALNY Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patie… https://t.co/qPTBweLgBn January 21st 2022, 12:01pm |
 |
@quantisnow $ALNY ? Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Pat… https://t.co/044JZN18aW January 21st 2022, 12:01pm |
|
@stock_titan $ALNY Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patie… https://t.co/268pSPTTE9 January 21st 2022, 12:01pm |
 |
@WebChronicleTo1 $ALNY Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patie… https://t.co/bfhw1INtMr January 21st 2022, 12:01pm |
|
@GetOnTrade $ALNY HC Wainwright & Co. Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $350 https://t.co/xsHMOoHr7d January 20th 2022, 10:01pm |
 |
@MC_OptionTrades $ALNY 21-Jan-22 Straddle Implies a ±2.7% move. Jan 21 Socit Francophone du Nerf Priphrique Annual Meeting https://t.co/guU4GWiQ50 January 20th 2022, 9:01pm |
 |
@BenzingaMedia $ALNY, $ALNY What 10 Analyst Ratings Have To Say About Alnylam Pharmaceuticals - https://t.co/eEtVyjDRQ7 January 20th 2022, 8:01pm |
 |
@MarketCurrents $ALNY - Alnylam price target raised by 40% at H.C. Wainwright citing upcoming catalysts https://t.co/VPDZW7nepX January 20th 2022, 7:01pm |
|
@Tickeron $ALNY enters a Downtrend because Momentum Indicator dropped below the 0 level on December 27, 2021. View odds for t… https://t.co/OsohCXoWKu January 20th 2022, 6:01pm |
 |
@LargeVoidBot Daily Reversal (10:22): $ALNY Last: 144.25; pHigh: 144.20; rVol: 1.256; pClose: 138.60; LOD: 142.8100; Perf: 4.1% January 20th 2022, 3:01pm |
 |
@GenevaSimon19 $ALNY *Hey guys, I've made $55K with them in a week, by their alerts ,._, https://t.co/8N0z3lY2LF January 20th 2022, 2:01pm |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2022. All rights reserved.
DrugPatentWatch Video Training
Decision-making for generic drug entry and branded drug lifecycle management
By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
This course answers the following questions to help you adapt:
- ✓ When will key drug patents expire?
- ✓ How can I find, evaluate, and plan for generic market entry opportunities?
- ✓ How can I find proprietary out-of-court settlements and deal terms?